AMA Will Issue New CPT Code for AI Prostate Cancer Mapping Tool
The Current Procedural Terminology (CPT) Category III code for the Unfold AI prostate cancer mapping platform can be utilized by radiologists starting in July 2024.
The 2024 Current Procedural Terminology (CPT) codes from the American Medical Association (AMA) will include a new category III CPT code for the use of Unfold AI, an artificial intelligence (AI)-enabled mapping platform for prostate cancer imaging.
Unfold AI is reportedly the first AI-powered prostate cancer modality to receive a category III CPT code, according to Avenda Health, the manufacturer of Unfold AI.1
Avenda Health said the X237T CPT code, which goes into effect in July 2024, can be utilized for “Non-invasive prostate cancer estimation map, derived from augmentative analysis of image-guided fusion biopsy and pathology, including visualization of margin volume and location, with margin determination and physician interpretation and report.”
"The new CPT code solidifies our position as a frontrunner in revolutionizing cancer care and our commitment to making our technology accessible to all patients,” noted Brittany Berry-Pusey, Ph.D., the COO and co-founder of Avenda Health.
In a retrospective study published earlier this year, researchers found that AI model margins with Unfold AI demonstrated a 96.9 percent sensitivity for diagnosing clinically significant prostate cancer (csPCa) in comparison to 37.4 percent for regions of interest (ROI) on conventional magnetic resonance imaging (MRI).2
References
1. Avenda Health. Avenda Health’s revolutionary AI mapping tool for prostate cancer achieves landmark category III CPT code designation. Cision PR Newswire. Available at: https://www.prnewswire.com/news-releases/avenda-healths-revolutionary-ai-mapping-tool-for-prostate-cancer-achieves-landmark-category-iii-cpt-code-designation-301973699.html . Published November 1, 2023. Accessed November 1, 2023.
2. Hall J. Study says AI mapping more effective than MRI for assessing extent of prostate cancer. Diagnostic Imaging. Available at: https://www.diagnosticimaging.com/view/study-says-ai-mapping-more-effective-than-mri-for-assessing-extent-of-prostate-cancer . Published June 15, 2023. Accessed November 1, 2023.
Expanded FDA Approval Allows Use of Pluvicto Prior to Chemotherapy in Patients with mCRPC
March 28th 2025Recent research demonstrated a 59 percent reduced risk of progression or death with the radioligand therapy Pluvicto in comparison to a change of androgen receptor pathway inhibitor (ARPI) for patients with metastatic castration-resistant prostate cancer (mCRPC).
Study: Monitoring of Prostate MRI Exams Could Lead to 75 Percent Reduction of Gadolinium Contrast
March 17th 2025While DCE MRI was deemed helpful in over 67 percent of cases in which it was used, researchers found that monitored prostate MRI exams, which facilitated a 75 percent reduction of DCE MRI sequences, had comparable sensitivity for prostate cancer as non-monitored exams.
Meta-Analysis Shows No Difference Between bpMRI and mpMRI in Ruling Out csPCa
March 6th 2025In an 18-study meta-analysis involving over 4,600 patients, researchers found that bpMRI and mpMRI had equivalent pooled negative predictive value (NPV) of 92 percent for clinically significant prostate cancer (csPCa).
